ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1413

The Prevalence of Renal Impairment in Patients with Rheumatoid Arthritis

Marion Couderc Sr.1, Martin Soubrier2, Bruno Pereira3, Aurelien Tiple4, Melanie Gilson5, Bruno Fautrel6, Sophie Pouplin7, Emmanuelle Dernis Labous8, Laure Gossec9, Cécile Gaujoux-Viala10 and Maxime Dougados11, 1Chu G.Montpied, Clermont Ferrand, France, 2Rheumatology, CHU G.-Montpied, Clermont-Ferrand, France, 3Clinical research department, Clermont-Ferrand, France, 4Nephrology, CHU, Clermont-Ferrand, France, 5Rheumatology, CHu Grenoble, Grenoble, France, 6Rheumatology, Pitie Salpetriere Hospital, Paris, France, 7Rheumatology, Rouen University Hospital, Rouen, France, 8Rhumatologie, Ch Du Mans, Le Mans, France, 9Rheumatology, UPMC GRC08, Paris 06 University, Pitié Salpétrière Hospital, Paris, France, 10EA 2415, Montpellier I University, Nîmes University Hospital, Rheumatology Department, Nîmes, France, 11Université Paris René Descartes and Hôpital Cochin, Paris, France

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Cardiovascular disease, renal disease and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis - Clinical Aspects (ACR): Comorbidities, Treatment Outcomes and Mortality

Session Type: Abstract Submissions (ACR)

Background/Purpose: To assess the prevalence and associations of renal dysfunction in patients with rheumatoid arthritis (RA).

Methods: COMEDRA is a French nationwide cross-sectional multicentre study on comorbidities in RA. Renal function was assessed from the estimated glomerular filtration rate (eGFR) using the Modification of Diet in Renal Disease (MDRD) equation. RA characteristics, risk factors for renal dysfunction (cardiovascular risk factors, medications) were collected in all participants.

Results: 931 of the 970 recruited patients, were analysed (female gender: 79.6%, age: 57.8 years, disease duration: 11.1 years, DAS28-erythrocyte sedimentation rate: 3.1). About 9 % of patients had an eGFR<60 ml/min/1.73m2 and 9.9% of the patients had proteinuria (defined by positive dipstick testing). In the univariate analysis, age (p<0.001), the presence of hypertension (p<0.001), systolic blood pressure (p=0.03), and Framingham Risk score (p<0.001) were associated with an eGFR<60ml/min/1.73m2. Renal dysfunction was not associated with gender (p=0.35), disease duration (p=0.91), disease activity (as assessed by DAS28-ESR: p=0.14), NSAID use (p=0.77), disease severity (erosions [p=0.9], joint replacement [p=0.6]) or RA medications (p=0.14). Two multivariate analysis models were constructed: Model A, without the Framingham risk score which showed that age (OR: 1.05; 95%CI [1.03-1.09]) and hypertension (OR: 2.5, 95%CI [1.5-4.3]); were predictive of an eGFR <60 ml/ min/1,73m2; Model B, which showed that the Framingham risk score was predictive of low eGFR (OR 1.06, 95%CI [1.03-1.09]).

Conclusion: Renal impairment is relatively common in RA and is associated with cardiovascular risk factors such as age, hypertension and the Framingham risk score but not with disease activity or severity.


Disclosure:

M. Couderc Sr.,
None;

M. Soubrier,
None;

B. Pereira,
None;

A. Tiple,
None;

M. Gilson,
None;

B. Fautrel,
None;

S. Pouplin,
None;

E. Dernis Labous,
None;

L. Gossec,
None;

C. Gaujoux-Viala,
None;

M. Dougados,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-prevalence-of-renal-impairment-in-patients-with-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology